PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Modifiable factors”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources
PubMed1993

Age as a modifying factor on the effect of antihypertensive therapy in focal stroke in rats.

BACKGROUND AND PURPOSE: Antihypertensive treatment with hydralazine for 10 weeks but not 6 weeks reduces infarct size in 13-week-old spontaneously hypertensive rats subjected to focal cerebral ischemia. This study was designed to examine whether the duration of treatment needed to reduce infarct size depends on how long hypertension is present before the initiation of antihypertensive therapy. METHODS: Six-week-old spontaneously hypertensive rats were treated for 6 weeks and 10-month-old spontaneously hypertensive rats for 10 weeks with 20 mg/kg hydralazine added daily to the drinking water. The animals were then subjected to focal cerebral ischemia by tandem permanent common carotid and middle cerebral artery occlusion. RESULTS: Blood pressure in the treated groups was lower than that in the untreated groups for the entire treatment period in both experiments. Infarct volume in 10-month-old spontaneously hypertensive rats treated for 10 weeks, but not in 6-week-old spontaneously hypertensive rats treated for 6 weeks, was significantly less than in untreated controls (p = 0.02). CONCLUSIONS: This study emphasizes the importance of duration of antihypertensive treatment in reducing infarct volume in spontaneously hypertensive rats after focal cerebral ischemia and demonstrates that the effect appears to be independent of the duration of hypertension before the initiation of treatment.

Age Factors↗
PubMed1987

Factors modifying the prognosis of Wilson's disease in childhood.

The prognosis of Wilson's disease was investigated in 96 patients, in whom the disease had presented before 15 years of age and had begun between 1965 and 1983 (when D-penicillamine was widely available in Japan). In the activities of daily living, the prognosis was poor in those patients presenting with neurological symptoms. Interruption of D-penicillamine treatment was seen in one third of the patients, and it worsened the prognosis. Toxic side effects were seen in about half of the patients, being more frequent in the patients with initial neurological symptoms. A disappointing 17% of patients with slight or no side effects discontinued the drug. Death occurred in eight patients of whom seven had had initial hepatic symptoms. Not only early diagnosis and treatment before the appearance of hepatic failure or neurological symptoms, but also treatment throughout life without interruption is important for improving the prognosis of Wilson's disease.

Adolescent↗
PubMed2002

Experiences of families in which a child has a prolonged terminal illness: modifying factors.

A significant proportion of children requiring palliative care have neurodegenerative life-threatening illnesses (NLTIs). While most of their care is provided at home by their families over many years, there is a paucity of research examining families' experiences when a child with an NLTI is dying at home. In this grounded theory study, data were collected from eight families through observations and audiotaped interviews. Families moved through a process of 'navigating uncharted territory' as they lived with their dying child. The strategies that families used to manage this phenomenon were influenced by four intervening conditions that reflected the broader structural context of the phenomenon; relationships with healthcare providers, availability of information, gender differences, and communication between parents. Each condition facilitated or constrained the strategies that families were able to use. Implications for research, education and practice are discussed.

Child↗
PubMed1992

The adult respiratory distress syndrome. A report of survival and modifying factors.

The adult respiratory distress syndrome (ARDS) is a form of acute lung injury characterized by arterial hypoxemia, reduced thoracic compliance, normal pulmonary capillary wedge pressure, and diffuse infiltrates on chest roentgenograms. Mortality remains high and has been associated with sepsis, organ failure, age, and predisposing factors. We prospectively identified 215 ARDS patients over 34 months to examine how these factors influence outcome. One hundred two (47 percent) of 215 patients survived. Age 65 years or older was associated with a survival of 34 percent, which was statistically different from the 53 percent survival of those patients younger than 65 years (p = 0.02). Aspiration pneumonia as a predisposing factor of ARDS was associated with a better survival (p = 0.04). Survivors had statistically less organ failure and sepsis than did nonsurvivors (p less than 0.05). Cause of death was determined using the criteria of Montgomery et al for irreversible organ dysfunction. Forty-five (40 percent) of our patients died of respiratory failure (not sepsis). We conclude the following: (1) survival in our ARDS patients is different from previous reports; (2) the cause of death in our ARDS patients is different from that reported by Montgomery et al in 1985; and (3) multisystem organ failure, sepsis, age, and some predisposing factors of ARDS continue to be associated with decreased survival of ARDS patients.

Age Factors↗
PubMed1998

Osteoporosis: a possible modifying factor in oral bone loss.

There has been increasing interest in the interrelationship between systemic osteoporosis, oral bone loss, tooth loss, and risk factors for these conditions. Because the severity of alveolar bone loss increases with age, it has long been hypothesized that it may, in part, be related to systemic conditions that also predispose the patient to osteoporosis/osteopenia. The purpose of this paper is to review the risk factors for osteoporosis and periodontitis, as well as the evidence that loss of oral bone mineral may be related to systemic osteopenia. There is also evidence that therapies designed to influence systemic bone mineral density, such as hormone replacement and bisphosphonate therapy, may be associated with less tooth loss and a slower loss of alveolar bone, respectively.

Alendronate↗